The Eye Tracking System

Precision Diagnosis

(Oculomotricity)

The eye tracker monitors attention during different eye movement tasks and can assess an individual whether his or her performance is in a disease range (e.g., ADHD or Alzheimer’s disease) or a normal range.

The device used in this clinic is a Class IIa CE medical device that fulfills conformity assessment under the European Union's Medical Device Regulation (MDR).

Professional and technical

Oculomotricity

An oculomotricity device records eye movements. The device used in this clinic is a Class IIa CE medical device that fulfills conformity assessment under the European Union's Medical Device Regulation (MDR).
Each eye movement can be captured independently by recording the horizontal and vertical position of the eye.
The recording frequency for both eyes is 300 Hz.
Calibration is done at the beginning, and the visual tasks will be done immediately after calibration.
Analysis software will be used to automatically determine the onset and end of each saccade, using its built-in saccade detection algorithm.
Saccade latencies (time between the onset of the target and beginning of eye movement), the average speed of saccade, anticipatory saccades (saccade latencies of <80ms after target appearance), and direction errors (saccades made towards the stimulus, erroneous prosaccades) will be extracted for analysis.
The psychiatrist will determine how many parameters are in the disease range or within the healthy range.

Academic paper

publications

The eye tracker was validated in previous studies where Dr. Ho is a co-author, and the detailed performance of the system was also mentioned in the following academic paper:

Ma G, Eng AE, Chiang SK, Hao F, McIntyre RS, Zhou D, Yang Y, Ho RC, Yam KC. A comparative diagnostic study using clinical and multimodal assessment, including functional neuroimaging and oculomotricity tools, to differentiate ADHD in young patients from healthy control group. Psychiatry Clin Neurosci. 2025 Apr;79(4):165-175. doi: 10.1111/pcn.13788. Epub 2025 Feb 4. PMID: 39901842.

Disclaimer:

At THMC Mental Health & Innovation Service, the adoption of innovative technologies, including functionalized near-infrared spectroscopy (fNIRS), eye tracking, and computerized neurocognitive testing as assessment tools for Attention Deficit Hyperactivity Disorder (ADHD) is subject to the following terms:

1. Research Basis: The technologies outlined herein are utilized based on findings from the research article published in Psychiatry and Clinical Neurosciences in 2025. These findings demonstrate the efficacy of combining three objective markers—fNIRS, eye tracking, and computerized tests—along with seven objective parameters to distinguish adults with ADHD from healthy controls, achieving a sensitivity of 80.28% and specificity of 84.51%.
2. No Guarantee of Results are Positive for ADHD: While these technologies have shown promising results in research settings, their effectiveness may vary in individual cases. The adoption of these methods does not guarantee a diagnosis of ADHD or any other condition. The assessment tools may yield normal findings despite the person complains of inattention or hyperactivity.
3. Clinical Judgment: The interpretation of results from these technologies must be conducted by qualified healthcare professionals. These tools are intended to complement, not replace, clinical assessments and professional judgment.
4. Limitations and Risks: Users of these technologies should be aware of potential limitations, including but not limited to variability in test performance and the influence of external factors on results. Concerns about risks associated with testing and interpretation should be discussed with a healthcare provider.
5. Liability: THMC Mental Health & Innovation Centre shall not be liable for any direct or indirect consequences arising from the use of these technologies in ADHD diagnosis. Users assume all risks associated with the interpretation and use of data derived from these assessments.
6. Continued Research: Ongoing research is necessary to further validate these technologies and their application in clinical settings. Users are encouraged to stay informed about updates in research findings and clinical practices.

By utilizing these technologies, you acknowledge and accept the terms of this legal disclaimer.

Precision Diagnosis